Based on the data, I would recommend a SELL for the stock of Sun Pharmaceutical Industries Limited. Here's my thought process:

1. **Valuation**: The trailing PE ratio of 36.48 is higher than the industry average, indicating that the stock is already pricey. The forward PE ratio of 50.85 is even more concerning, suggesting that the market expects the company's earnings to decline in the future.

2. **Profitability**: Although the profit margin of 20.79% is decent, the return on equity (ROE) of 15.71% is relatively low. This suggests that the company is not generating sufficient returns on its shareholders' equity.

3. **Growth**: The revenue growth rate of 8.1% is modest, but the earnings growth rate of -18.8% is a major red flag. This indicates that the company's earnings are declining, which could lead to a decrease in stock price.

4. **Leverage**: The debt-to-equity ratio of 3.26 is high, indicating that the company has a significant amount of debt on its balance sheet. This could lead to increased risk and reduced financial flexibility.

Considering these factors, I believe that the stock is overvalued and has poor growth prospects. Hence, I would recommend a SELL for Sun Pharmaceutical Industries Limited.